VEGF及其受体与肝细胞癌血管生成和抗血管治疗研究进展.pdf

498
陈杰,等VECF及其受体与肝细胞癌血管生成和抗血管治疗研究进展
708
21 Lassau N, Chari L, Benatsou B, et al. Dynamic contrast-en
9 Maffione AM, Ferretti A, Grassetto C, el al. Fifteen different F
hanced ultrasonography(dce-us)with quantification of Lumor
FDG PET/CT qualitative and quantitalive parameters investigated
perfusion: A new diagnostic tool to evaluate the carly effects of
pathological response predictors of locally advanced rectal canc-
antiangiogenic treatment J]. Eur Radiol, 2007, 17(6): 89-98
er treated by neoadjuvant chemoradiation therapy[J i. Eur .I Nuc! [22] Onji K, Yoshida S,, Tanaka S, et al. Microvascular structure and
Med Mo] Imaging,2013,40(6):853-864.
perfusion imaging of colon cance
means
20] Cartana ET, Parvu 1), Saftoiu A. Endoscopic ultrasound current
hanced ultrasonography[ J]. Abdom Imaging, 2012, 37(2): 297
role and future perspectives in managing rectal cancer patients
IJ. J Gastrointestin Liver Dis, 2011, 20(4): 407-413
(编校:玥)
VEGF及其受体与肝细胞癌血管生成和抗血管治疗研究进展
陈杰,侯恩存
Progress of VEGF and its receptors in HCC angiogenesis and antiangiogenesis therapy
Chen Jie Hou Encun
Department oncology, Ruikang Hospital Af ted o Gung n es of rd n nse Medc ne, ung anng530011
China
(Abstractthe development of hepatocellular carcinoma(HCC) is closely related to angiogenesis of tumors, vascular
endothelial growth fac or(VEG). Its receptor involves directly or indirectly in angiogenesis of HCC with a strong pro
moting function and plays very important role on the occurrence, development and prognosis of HCC In reeent years,
tumor antiangiogenesis therapy targeted on VEGF and its receptors is a hotspot in EICC treatment. This paper aims to
make a review on related research progress of VEGF and its receptors in HCC angiogenesis and antiangiogenesis therapy
Key words) vascular endothelial growth factor(EG), vascular endothelial growth actor receptor(VEGFR), hepa-
tocellular careinoma(HCC), antiangiogenesis therapy
Modern Oncology2016,24(03):0498-0502
【指示性摘要】肝细胞癌( hepatocellular carcinoma,HC)发牛发展与肿瘤血管生成密切相关,而血管内皮生长
因子( vascular endothelial growth factor,VECF)及其受体能直接或间接参与肝癌血管生成,且具有很强的促进
作用,在肝癌的发生、发展及预后中扮演着极其重要的角色。近年米,以 VEGF及其受体为靶点的肿樒抗血管
治疗是HCC治疗研究的热点。本文复习近十年相关文献,对VEGF及其受体与HCC肿瘤血管生成和HC抗
血管治疗相关研究进展作简要综述。
【关键词】血管内皮生长因子;血管内皮生长因子受体;肝细胞癌;抗血管治疗
中图分类号)R735.7
文献标识码)A
DOI:10.3969/j.issn.1672-4992.2016.03.048
【文章编号」1672-4992-(2016)03-0498-05
肝细胞癌( hepatocellular carcinoma,IC)是常见恶性肿位。我国属于肝癌高发地区,据《2)14世界癌症报告》统
之一,预后差,生存时间较短,排全球肿瘤致死原因第
计,全世界约一半的新增肝癌病例出现在中国,尤其是乙型
肝炎进展演变引起的肝癌。目前,唯一能治愈HCC的方法
【收稿日期】2015-08-19
是对早期患者行根治性手术和肝移植,但由于缺少针对早期
基金项目】广西自然科学基金项目(编号:201 IGXNSFA018280)
患者审慎、有效的诊断方法,大部分患者就诊时已至中晚期,
〔作者单位」广ヴ中医药大学附属瑞康医院肿瘤科,广西南宁
术后均存在一定的复发风险,因此积极探索IC其它有效
【作者简介】陈杰(1989-),男,湖北黄冈人,医师,在读硕士,主要治労方法迫在肩睫。HCC的分子水平发病机制以及相关分
从事中西医肿瘤内科工作。E-mail:-467419344@qq
子靶向治疗一直是当前热门研究方向之…,其中,血管内皮
生长因子(VECF)及其受体( VEGFR)作为HCC抗血管治疗
通讯作者】侯恩存(1968-),男,山东菏泽人,主任医师,硕士生的重要靶点,近来也倍受关注。本文收集近十年相关文献
导师,主要从事中西医肿瘤内科工作。E-mail
从VEGF及其受体与HCC肿瘤血管的生成和在HCC抗血管
houec2008(@sina.com
治疗中的应用两方面对其相关研究进展进行简要综述。